News

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability.

Clinically meaningful improvements in global IBS symptom severity were observed as early as week 1 and sustained through week 7.

This study evaluated the drug survival of different biologic therapies for patients with psoriasis in a routine clinical practice setting.

The Q4 recap for gastroenterology spotlights GI FDA news, new AGA guidelines, trial data for UC therapies, and more.

Meta-analysis shows exercise may match therapy in improving depressive symptoms, with moderate-intensity and 13–36 sessions offering the greatest benefit.

Osborne discusses the background behind fenofibrates’ approval for cardiovascular event reduction, despite no evidence supporting their efficacy.

Investigators look at the ways in which CSU impacts family members supporting those with CSU, using the Family Dermatology Life Quality Index (FDLQI).

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content.

A study found that low-intensity transcranial ultrasound stimulation targeting the left dlPFC improves depression while avoiding common side effects associated with TMS and tDCS.

Study findings highlight the importance of etiology-based chronic pancreatitis management, with NARCP linked to worse mortality, EPI, and other clinical outcomes.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients.

The Q4 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

This updated approval builds on the success of Fibryga’s 2024 approval for AFD, which was based on positive data from the phase 3 FIBRES trial.

The investigational antisense oligonucleotide met the primary endpoint for functional cure rate in the phase 3 B-Well 1 and B-Well 2 trials in chronic hepatitis B.

The FDA grants priority review of Vera Therapeutics’s Biologics License Application for the B-cell modulating, atacicept, in IgAN.

Q4 2025 psychiatry highlights: FDA approvals, clearances, and submissions, plus new clinical data shaping personalized treatment in MDD, bipolar, and schizophrenia.

The Q4 recap for hepatology spotlights new AASLD guidelines, changes to CDC hepatitis B vaccination recommendations, and more.

Kohli discusses the importance of the FDA’s recent label change and how clinicians can help reduce the continued prescription of ineffective medication.

The pulmonology year in review highlights FDA approvals and pivotal data readouts.

This study highlights the efficacy and safety of deucravacitinib 6 mg in psoriasis, with results stratified by body mass index and age in a Japanese patient cohort.

Retrospective data suggest serum creatinine trajectories might predict 28-day mortality in acute kidney injury on chronic kidney disease.

A study found no differences in depressive symptom reduction when nonresponders continued therapy, switched therapists, or changed both therapist and treatment approach.

Catch up on IBD steroid exposure risk, intensive weight loss before colorectal cancer surgery, a new chronic idiopathic constipation treatment option, and more.

Zeidan discusses the interim results from the ongoing phase 1/2 trial, highlighting bexmarilimab’s efficacy in combination with azacitidine SoC.

A cross-sectional study in CKD suggests patients undergoing hemodialysis have increased social frailty and depression compared to transplant recipients.

Two phase 3 trials met their primary and secondary endpoints in patients with moderate-to-severe plaque psoriasis on envudeucitinib.

Crohn’s & Colitis Foundation survey findings show 18% of young adults with IBD work extra hours to afford care and > 1 in 3 are not confident navigating insurance.